Press releaseMar 20, 2026Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipelineProposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,…
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epi...
Publisher
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epi...
Source route
Continue on novartis.com
Leave the platform to read the original full article on the publisher site.
Source: Novartis News
Scope: Industry
Related coverage
More related coverage
Mar.23.2026R & DBristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo®(nivolumab)
This material is intended to notify the press release issued on March 20 (local time) by Bristol Mye...
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarb...
Financial Tear Sheet
Financial Tear Sheet – Bausch Health Companies Inc.
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 w...